ICOSAPENT ETHYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ICOSAPENT ETHYL (ICOSAPENT ETHYL).
Icosapent ethyl is a prodrug of eicosapentaenoic acid (EPA), which reduces hepatic very low-density lipoprotein (VLDL) triglyceride synthesis and/or secretion, and increases clearance of triglycerides from chylomicrons and VLDL particles. It also reduces apolipoprotein B and cholesterol synthesis in the liver.
| Metabolism | Icosapent ethyl is hydrolyzed by intestinal carboxylesterases to EPA, which is further metabolized primarily via beta-oxidation and to a lesser extent via cytochrome P450 (CYP) enzymes. |
| Excretion | Primarily fecal as unchanged drug (approximately 90%). Minor renal excretion (<1%). Biliary excretion contributes to fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 89–174 hours (mean ~100 hours) after multiple doses, reflecting slow turnover of ethyl esters incorporated into lipoproteins. |
| Protein binding | Icosapent ethyl and its major metabolite are highly protein-bound (>99%), primarily to albumin. |
| Volume of Distribution | Apparent volume of distribution is not well defined; due to high lipophilicity, it distributes into adipose tissue and plasma lipoproteins; Vd estimated >1000 L. |
| Bioavailability | Oral: Systemic bioavailability is increased when taken with a high-fat meal (approximately ~50% higher compared to fasting). |
| Onset of Action | Oral: Therapeutic effects on serum triglycerides are seen within 2–4 weeks of daily dosing. |
| Duration of Action | Sustained reduction in triglycerides persists with continued dosing; effects diminish over weeks after discontinuation due to slow clearance. |
2 grams orally twice daily (4 grams/day).
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required; clinical studies included patients ≥65 years with similar safety and efficacy as younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ICOSAPENT ETHYL (ICOSAPENT ETHYL).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Caution advised; M/P ratio unknown. |
| Teratogenic Risk | Insufficient human data; animal studies show no evidence of fetal harm at clinically relevant doses. However, as with all drugs, use only if clearly needed during pregnancy. First trimester: no known risk. Second/third trimester: no known risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["History of hypersensitivity to icosapent ethyl or any component of the formulation"]
| Precautions | ["Increased risk of atrial fibrillation or flutter, particularly in patients with prior history","Potential for bleeding events; monitor patients receiving anticoagulants or antiplatelet agents","Allergic reactions have been reported; discontinue if hypersensitivity occurs"] |
Loading safety data…
| No specific fetal monitoring required. Monitor maternal triglycerides and potential bleeding risk due to antiplatelet effect. |
| Fertility Effects | No human studies on fertility. Animal studies show no impairment at clinically relevant doses. |